Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Methotrexate

Known as: Méthotrexate, 4-Amino-10-methylfolic Acid, 4-amino-N(10)-Methylpteroylglutamic acid 
An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Background Since the publication of the European League Against Rheumatism (EULAR) recommendations for the management of large… Expand
Is this relevant?
Review
2019
Review
2019
BACKGROUND & AIMS We performed a systematic review and meta-analysis to evaluate the comparative risk of serious infections with… Expand
Is this relevant?
Review
2019
Review
2019
Our objective was to update the EULAR recommendations for the management of systemic lupus erythematosus (SLE), based on emerging… Expand
Is this relevant?
Review
2019
Review
2019
Methotrexate has been used in treatment of rheumatoid arthritis (RA) since the 1980s and to this day is often the first line… Expand
Is this relevant?
Review
2018
Review
2018
Resistance to therapeutic agents, either intrinsic or acquired, is currently a major problem in the treatment of cancers and… Expand
  • figure 1
  • table 1
  • figure 2
Is this relevant?
Review
2018
Review
2018
  • J. Schmidt
  • Journal of neuromuscular diseases
  • 2018
  • Corpus ID: 46926504
Inflammatory disorders of the skeletal muscle include polymyositis (PM), dermatomyositis (DM), (immune mediated) necrotizing… Expand
  • table 2
  • figure 1
  • figure 2
Is this relevant?
Review
2018
Review
2018
Baricitinib (Olumiant®) is an oral, targeted synthetic DMARD that inhibits JAK1 and JAK2, which are implicated in the… Expand
  • table 1
  • table 2
Is this relevant?
Review
2018
Review
2018
BackgroundConventional pharmacological therapies for the treatment of juvenile idiopathic arthritis (JIA) consist of non… Expand
  • table 1
  • table 2
  • figure 1
Is this relevant?
Review
2017
Review
2017
Policy Points: Our study indicates that there are opportunities for cost savings in generic drug markets in Europe and the United… Expand
  • figure 3
Is this relevant?
Review
2017
Review
2017
Intravenous (IV) and subcutaneous (SC) tocilizumab (RoActemra®), an IL-6 receptor antagonist, are approved (± methotrexate) in… Expand
  • table 1
  • table 2
  • table 3
Is this relevant?